drugset / Trial / NCT01919684
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Phase 1
Completed
56 enrolled
Ligand Pharmaceuticals
Beckloff Associates, Inc. · collabMedpace, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to evaluate the safety and tolerability of a range of single oral doses of LGD-6972 in healthy subjects. Additionally, the study will characterize the Pharmacokinetic profile in healthy subjects under fed and fasted conditions and in subjects with Type 2 Diabetes Mellitus under fasted conditions.
Timeline
- Start
- 2013-11
- Primary completion
- 2014-02
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LGD-6972 | Small molecule | — | Oral |